Fideuram Asset Management Ireland dac Purchases New Holdings in Merck & Co., Inc. $MRK

Key Points

• Fideuram Asset Management Ireland dac opened a new position in Merck & Co. in the fourth quarter, buying 173,239 shares worth about $18.2 million. The stake makes up roughly 1.3% of its portfolio and is its 13th largest holding.
• Merck continues to attract heavy institutional interest, with large investors like Vanguard, Invesco, and Jennison also increasing or adding holdings. About 76% of the stock is owned by hedge funds and other institutional investors.
• Recent company developments have been generally positive, including shareholder approval of board nominees and executive pay, plus approval of Merck’s chicken bronchitis vaccine for use in China. Analysts remain broadly constructive, with a Moderate Buy consensus and an average price target of $128.18.

Fideuram Asset Management Ireland dac purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 173,239 shares of the company's stock, valued at approximately $18,235,000. Merck & Co., Inc. accounts for approximately 1.3% of Fideuram Asset Management Ireland dac's portfolio, making the stock its 13th largest position.

Other large investors also recently bought and sold shares of the company. DLD Asset Management LP raised its holdings in Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Jennison Associates LLC purchased a new position in Merck & Co., Inc. in the fourth quarter worth about $585,192,000. Invesco Ltd. raised its holdings in Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after buying an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock worth $1,336,877,000 after buying an additional 2,735,459 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after buying an additional 2,185,853 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Get Merck & Co., Inc. SMS alerts:

Sign Up

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow

Analysts Set New Price Targets

MRK has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a report on Monday, April 6th. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price for the company. Barclays initiated coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price for the company. Finally, Guggenheim lifted their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $119.87 on Friday. The company has a 50 day moving average price of $116.31 and a 200-day moving average price of $111.41. Merck & Co., Inc. has a 52 week low of $75.40 and a 52 week high of $125.14. The firm has a market capitalization of $296.05 billion, a PE ratio of 33.77, a P/E/G ratio of 2.71 and a beta of 0.18. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business posted $2.22 earnings per share. The business's revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.